United States · FDA National Drug Code directory
OGIVRI
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 83257-003_ed1bbb0a-ad1a-6cb6-e955-e9ae2ce9c40f
- Product NDC
- 83257-003
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Composition / generic term
- trastuzumab-dkst
- Labeler
- Biocon Biologics Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20231001
- Source listing expiry
- 20271231
Source-listed ingredients
- TRASTUZUMAB — 420 mg/20mL
These values do not establish equivalence or a dose recommendation.
Packages
Package details are not available in this snapshot.
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →